Innovent Biologics Showcases "Dual Innovations" at Oncology R&D Day, Pioneering the Future of Cancer Treatment with Next-Generation IO and ADC Platforms

SAN FRANCISCO and SUZHOU, China, June 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, held its Oncology R&D Day, unveiling its forward-looking strategy centered on dual innovation in next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) technologies. This strategic focus aims to redefine the standards of cancer treatment and propel Innovent toward becoming a global, premier biopharmaceutical leader. The event drew over 500 participants, including leading oncology key opinion leaders (KOLs), principal investigators, analysts, and global investors, signaling strong engagement with Innovent's transformative vision for the future of oncology.

"Over the past decade, Innovent has been at the forefront of China's biopharmaceutical evolution—pioneering the PD-1 immunotherapy era and building China's leading oncology brand, with over 3 million cancer patients treated with our therapies," said Dr. Michael Yu, Founder, Chairman of the Board and CEO of Innovent. "We are entering a new chapter focused on global innovation, powered by a robust pipeline and dual innovation of next-generation IO and next-generation ADC. Our recent presence at the 2025 ASCO with eight oral presentations highlights the strength and global competitiveness of our R&D. But this is only the beginning. With a clear vision to advance at least five pipeline assets into MRCT Phase 3 by 2030, we are committed to delivering innovative, high-quality, and accessible cancer treatments to patients worldwide."

Dual Innovation to Unlock the Future of Oncology: Next-gen IO + Next-gen ADC

At the core of Innovent's oncology strategy lies the dual engines of next-generation immunotherapy (IO) and next-generation antibody-drug conjugates (ADC), supported by deep insights in cancer biology and differentiated technology platforms.

"We are harnessing deep cancer biology insights, advanced antibody and protein engineering, and differentiated ADC linker-payload technologies to develop broader-spectrum, more potent, and less toxic therapies aimed at transforming the oncology treatment paradigm," said Dr. Zhou Hui, SVP of Innovent Oncology R&D. "Our strategy is designed to target some of the toughest challenges in cancer care, including drug resistance, cold tumors, and improve the efficacy of current IO treatment, while bringing new hope to patients worldwide."

Global R&D Roadmap: a Clear, Stepwise Development Strategy 

Innovent's pipeline is guided by a rational, phased IO+ADC combination strategy designed to address tumor heterogeneity and immune escape, evolving through three stages:

• Next-gen IO + Chemotherapy: to redefine the IO cornerstone
• Next-gen IO + mAb-ADC / bispecific ADC: to cover expansive tumor types and treatment lines
• Next-gen IO + Dual-Payload ADC (dpADC): to unlock full potential of IO+ ADC synergy, and reshape cancer treatment

Currently its oncology pipeline features nearly 10 next-generation molecules in global development, with multi-regional trials actively underway in the U.S., EU, and Asia. The company also continues to invest in global R&D infrastructure, supported by R&D hubs in Shanghai and San Francisco and antibody and ADC manufacturing capacity exceeding 140,000L.

Innovent is rapidly expanding its global innovation footprint, with a 2030 goal to advance at least five pipeline assets into global MRCT Phase 3 trials. Key potential candidates includes:

• IBI343: innovative CLDN18.2 ADC with site-specific conjugation and a TOPO1 inhibitor payload, demonstrating significant survival benefits in both GC and PDAC
• IBI363: PD-1/IL-2^α-bias fusion protein as next-gen IO to redefine cancer treatment and expand the boundaries of IO responsiveness
• IBI3009: DLL3 ADC in collaboration with Roche
• IBI3003: tri-specific T-cell engager targeting BCMA/GPRC5D/CD3 for multiple myeloma
• IBI3001: EGFR/B7H3 ADC with two synergetic targets covering multiple potential indications
• IBI3020: CEACAM5 dual-payload ADC as globally the first to enter clinical phase

IBI363: Next-Gen IO Redefining Cancer Immunotherapy

IBI363 is a global first-in-class PD-1/IL-2^α-bias fusion protein, featuring a differentiated molecular design and a dual immune activation mechanism. Emerging clinical data strongly support its mechanism of action in reinvigorating and expanding tumor-specific T cells (TSTs).

At ASCO 2025, IBI363 demonstrated breakthrough potential in three hard-to-treat tumor types, with a long tailing effect in prolonged survival benefits:

• Immune-resistant NSCLC (squamous & Adeno): boosted response rate and extended PFS reflects strong immune activation; median overall survival (mOS) up to 17.5 months in 1.5 mg dose cohorts, 12-month OS rate exceeding 70% for 3 mg dose cohorts, and benefit observed even in PD-L1 low expressers
• Later-line CRC (3L+): mOS of 16.1 months in monotherapy and only 17.8% OS events occurred in combination with bevacizumab with 9.4 months follow-up, outperforming historical benchmarks
• Immune-resistant melanoma (mucosal/acral subtypes): confirmed overall response rate (cORR) 23%, median duration of response (mDoR) 14 months, and median OS 14.7 months, showing unprecedented positive response and a long-lasting immunologic tailing effect

With two Breakthrough Therapy Designations from the NMPA CDE, two Fast Track Designations from the FDA, IBI363 is advancing rapidly toward registrational development. The first head-to-head trial vs. pembrolizumab in mucosal and acral melanoma was initiated. Meanwhile, IBI363 is in preparation for registrational trails in IO-treated squamous NSCLC, and third-line MSS colorectal cancer.  Additional trails for first-line and other solid tumors also under exploration in ongoing PoC studies.

High-Potency, Low-toxicity ADC Platforms Synergizing with IO for Broad Indication Coverage

Innovent is rapidly advancing its next-gen ADC pipeline, including:

• IBI343 (CLDN18.2 ADC): first in PDAC to demonstrate long-term survival benefits (mOS 12.1 months in 2L)
• IBI3001 (EGFR/B7H3 ADC): dual-targeted ADC with broad potential in solid tumors
• IBI3020 (CEACAM5 dual payload ADC): designed for high efficacy and low toxicity in treatment-resistant tumors

These programs leverage proprietary payloads and linkers, optimized for lower toxicity and high potency, and are poised to synergize with Innovent's IO agents to address broader and deeper indications.

Innovent Academy: R&D Engine to Drive Global Innovation

Innovent Academy is the company's discovery engine for driving global innovation. The Academy continues to expand its platforms in IO, ADC, T-cell engagers, and cytokines, firmly establishing its leadership in next-gen oncology discovery and translational science to generate 6–8 novel molecules per year.

Specifically, for next-gen IO and next-gen ADC dual upgradation, Innovent Academy focuses on:

• diversified antitumor mechanisms to integrate TME modulation and optimize IO efficacy;
• dual targeting approaches to overcome tumor heterogeneity and drug resistance.

This framework allows Innovent to systematically escalate efficacy and broaden tumor applicability, laying the foundation for first-in-class and best-in-class combination regimens for cancer treatments.

Catalyzing China's Role in Global Oncology Innovation

Leading oncology KOLs and principal investigators (PIs) delivered keynote speeches, reflecting on a pivotal moment for China's biotech industry. They emphasized that China's innovation, which is driven by rising translational capabilities, expanding global talent pools, and patient-centric trial execution, has entered a "Deepseek" moment, one where Chinese-discovered drugs can lead global standards, not just follow them.

"What we're witnessing is a profound shift," said one keynote speaker. "Innovent's next-generation IO programs like IBI363, with a clear global-first design, and ADC platforms targeting previously untreatable populations, show that Chinese biotech is poised to influence—not just participate in—the next global oncology paradigm."

The enthusiastic response from investors and KOLs underscores growing confidence in China-originated oncology innovation and reaffirms Innovent's position as it enters a new era of global innovation with a vision to become a global premier biopharmaceutical leader.

About Innovent

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 16 products in the market. It has 2 new drug applications (NDA) under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.

Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Statement:

1) Innovent does not recommend the use of any unapproved drug (s)/indication (s).

2) Ramucirumab (Cyramza) and Selpercatinib (Retsevmo) and Pirtobrutinib (Jaypirca) were developed by Eli Lilly and Company.

Statement:

1) Innovent does not recommend the use of any unapproved drug (s)/indication (s).

2) Ramucirumab (Cyramza) and Selpercatinib (Retsevmo) and Pirtobrutinib (Jaypirca) were developed by Eli Lilly and Company.

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions.

Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Innovent Biologics Showcases "Dual Innovations" at Oncology R&D Day, Pioneering the Future of Cancer Treatment with Next-Generation IO and ADC Platforms

Innovent Biologics Showcases "Dual Innovations" at Oncology R&D Day, Pioneering the Future of Cancer Treatment with Next-Generation IO and ADC Platforms

Innovent Biologics Showcases "Dual Innovations" at Oncology R&D Day, Pioneering the Future of Cancer Treatment with Next-Generation IO and ADC Platforms

Innovent Biologics Showcases "Dual Innovations" at Oncology R&D Day, Pioneering the Future of Cancer Treatment with Next-Generation IO and ADC Platforms

Innovent Biologics Showcases "Dual Innovations" at Oncology R&D Day, Pioneering the Future of Cancer Treatment with Next-Generation IO and ADC Platforms

Innovent Biologics Showcases "Dual Innovations" at Oncology R&D Day, Pioneering the Future of Cancer Treatment with Next-Generation IO and ADC Platforms

Innovent Biologics Showcases "Dual Innovations" at Oncology R&D Day, Pioneering the Future of Cancer Treatment with Next-Generation IO and ADC Platforms

Innovent Biologics Showcases "Dual Innovations" at Oncology R&D Day, Pioneering the Future of Cancer Treatment with Next-Generation IO and ADC Platforms

Innovent Biologics Showcases "Dual Innovations" at Oncology R&D Day, Pioneering the Future of Cancer Treatment with Next-Generation IO and ADC Platforms

Innovent Biologics Showcases "Dual Innovations" at Oncology R&D Day, Pioneering the Future of Cancer Treatment with Next-Generation IO and ADC Platforms

Innovent Biologics Showcases "Dual Innovations" at Oncology R&D Day, Pioneering the Future of Cancer Treatment with Next-Generation IO and ADC Platforms

• CATL opens Middle East's first NING SERVICE Experience Center in Riyadh —currently the largest new energy aftermarket facility outside China.
• The facility offers comprehensive full-lifecycle after-sales support, cultivates local technical talent and accelerates the deployment of advanced electrification and energy storage solutions.
• It also functions as a regional ecosystem hub linking diverse stakeholders and resources to drive industrial synergy and sustainable growth.

RIYADH, Saudi Arabia, Jan. 11, 2026 /PRNewswire/ -- On January 10, 2026, CATL opened the Middle East's first and currently the largest new energy aftermarket facility outside China—the NING SERVICE Experience Center in Riyadh—strengthening its after-sales presence in the Middle East and supporting the region's shift toward cleaner energy systems.

The opening comes as Saudi Arabia and the wider Middle East advance ambitious electrification and decarbonization goals under Vision 2030 and similar national initiatives. Taking Saudi Arabia as an example, The Kingdom has set a goal to transition 30% of all vehicles in Riyadh to electric by 2030, as part of a larger strategy to reduce emissions in the capital city by 50%. Sustainability policies are also driving the shift to electric equipment, such as promoting the use of electric forklifts, while encouraging the use of green energy on farms under the Saudi Green Initiative. However, progress is tempered by persistent challenges, including longstanding oil dependency, surging electricity demand, extreme climatic conditions, and limited charging and service infrastructure.

Strategically designed to overcome these obstacles, the Riyadh facility offers comprehensive full-lifecycle after-sales support, cultivates local technical talent and accelerates the deployment of advanced electrification and energy storage solutions. 

Covering more than 7,000 square meters, the Riyadh center combines exhibition areas, diagnostics and maintenance zones, refurbishment facilities, training spaces, and a customer lounge. It is designed to serve not only as a localized service hub for the region and a showcase of CATL's system-level capabilities across electric mobility, energy storage, and intelligent electrification, but also as a platform that links diverse resources, fostering industrial synergy across the ecosystem.

A full-lifecycle approach to new energy services

Relying on CATL's deep R&D and extreme manufacturing capabilities, NING SERVICE Experience Center provides customers with full-lifecycle services that encompass battery diagnostics, repair, maintenance, rework, training, recycling, aftermarket logistics and warehousing. Its services span over seven major product categories—from passenger and commercial vehicles to energy storage systems—along with diverse repair scenarios, setting a new benchmark for new energy service delivery in the region.

Leveraging CATL's advanced diagnostics and repair expertise, along with established service processes, the center's comprehensive after-sales services

helps enterprise customers reduce downtime, lower maintenance costs, and extend asset life, providing greater certainty around long-term performance and residual value while reducing long-term ownership costs and delivering more cost-effective and reliable services for end users.

Advancing localized operations and capability building

The Riyadh center serves as a key platform for CATL's localized operations in the Middle East, supporting talent development and long-term local value creation. Through dedicated training facilities, CATL builds after-sales and technical expertise in the new energy sector, contributing to skilled employment and knowledge transfer across the Middle East. Globally, NING SERVICE operates 10 training centers, totalling 2,300 square meters, and has certified more than 9,700 new energy after-sales professionals through partnerships with vocational institutions.

Beyond talent development, CATL is deepening its localization strategy by reinforcing local infrastructure and building ecosystem partnerships. CATL is in discussion with top-tier local industry players—including fuel network operators to rapidly provide green electricity to gas stations and major infrastructure companies to electrify their truck fleets, as well as energy companies to deploy solar-plus-storage solutions.

These initiatives not only bolster CATL's local service capabilities and market confidence, but also by enabling key partners, jointly drive the scaled adoption of comprehensive new energy solutions across the Middle East.

"As a leading energy company in Saudi Arabia, we see tremendous opportunities in energy transformation. For instance, we plan to deploy solar-plus-storage solutions at our gas stations and electrify forklifts to reduce reliance on oil. We look forward to collaborating with top players like CATL to drive this transition forward," said Ahmed Ibrahim，Assistant General Manager For Procurement of Al Drees, a leading provider of petroleum and logistics services in Saudi Arabia.

"The launch of CATL's Riyadh aftermarket flagship underscores our shared commitment to driving the global energy transition. This milestone not only reflects the growing demand for sustainable solutions in Saudi Arabia but also embodies our collective vision for a cleaner, electrified future. As the investor behind the experience centre, we are confident that this partnership will accelerate electrification and strengthen the region's role in advancing the energy transition." said Lin Chaofan, CEO of F4S. 

Part of a global network

The Saudi Arabia opening builds on CATL's global service footprint, which includes more than 1,200 professional service stations across 76 countries and 73 spare-parts warehouses worldwide. CATL ranks No. 1 globally in spare parts inventory stocked with 100% genuine parts, with a total warehouse area of more than 370,000 square meters. To date, NING SERVICE has supported more than six million electric vehicles, providing professional after-sales services for passenger vehicles, commercial vehicles, and energy storage customers.

A long-term commitment to the Middle East

Bruce Li, President of Quality System, Aftermarket Business, Battery Management System Department at CATL, said the Riyadh center reflects a strategic, long-term view of the region.

"Our decision to establish this center in Riyadh is not only a commercial choice, but a long-term commitment," Li said. "As the first NING SERVICE Experience Center in the Middle East, it is more than a service facility. It is a new energy aftermarket ecosystem hub that brings together advanced technology, professional training, and industry collaboration—effectively connecting diverse stakeholders and resources to foster deeper synergy and sustainable growth across the region. Starting from here, CATL will continue to expand its after-sales service network across the Middle East, align closely with Saudi Arabia's Vision 2030, and support the region's energy transition through a reliable, end-to-end service system."

As the Middle East accelerates its shift toward electrification and energy storage adoption, CATL's expanded NING SERVICE presence is poised to deliver the technical reliability and sustained partnerships essential for this transformation.

 

RIYADH, Saudi Arabia, Jan. 11, 2026 /PRNewswire/ -- On January 10, 2026, CATL opened the Middle East's first and currently the largest new energy aftermarket facility outside China—the NING SERVICE Experience Center in Riyadh—strengthening its after-sales presence in the Middle East and supporting the region's shift toward cleaner energy systems.

The opening comes as Saudi Arabia and the wider Middle East advance ambitious electrification and decarbonization goals under Vision 2030 and similar national initiatives. Taking Saudi Arabia as an example, The Kingdom has set a goal to transition 30% of all vehicles in Riyadh to electric by 2030, as part of a larger strategy to reduce emissions in the capital city by 50%. Sustainability policies are also driving the shift to electric equipment, such as promoting the use of electric forklifts, while encouraging the use of green energy on farms under the Saudi Green Initiative. However, progress is tempered by persistent challenges, including longstanding oil dependency, surging electricity demand, extreme climatic conditions, and limited charging and service infrastructure.

Strategically designed to overcome these obstacles, the Riyadh facility offers comprehensive full-lifecycle after-sales support, cultivates local technical talent and accelerates the deployment of advanced electrification and energy storage solutions. 

Covering more than 7,000 square meters, the Riyadh center combines exhibition areas, diagnostics and maintenance zones, refurbishment facilities, training spaces, and a customer lounge. It is designed to serve not only as a localized service hub for the region and a showcase of CATL's system-level capabilities across electric mobility, energy storage, and intelligent electrification, but also as a platform that links diverse resources, fostering industrial synergy across the ecosystem.

A full-lifecycle approach to new energy services

Relying on CATL's deep R&D and extreme manufacturing capabilities, NING SERVICE Experience Center provides customers with full-lifecycle services that encompass battery diagnostics, repair, maintenance, rework, training, recycling, aftermarket logistics and warehousing. Its services span over seven major product categories—from passenger and commercial vehicles to energy storage systems—along with diverse repair scenarios, setting a new benchmark for new energy service delivery in the region.

Leveraging CATL's advanced diagnostics and repair expertise, along with established service processes, the center's comprehensive after-sales services

helps enterprise customers reduce downtime, lower maintenance costs, and extend asset life, providing greater certainty around long-term performance and residual value while reducing long-term ownership costs and delivering more cost-effective and reliable services for end users.

Advancing localized operations and capability building

The Riyadh center serves as a key platform for CATL's localized operations in the Middle East, supporting talent development and long-term local value creation. Through dedicated training facilities, CATL builds after-sales and technical expertise in the new energy sector, contributing to skilled employment and knowledge transfer across the Middle East. Globally, NING SERVICE operates 10 training centers, totalling 2,300 square meters, and has certified more than 9,700 new energy after-sales professionals through partnerships with vocational institutions.

Beyond talent development, CATL is deepening its localization strategy by reinforcing local infrastructure and building ecosystem partnerships. CATL is in discussion with top-tier local industry players—including fuel network operators to rapidly provide green electricity to gas stations and major infrastructure companies to electrify their truck fleets, as well as energy companies to deploy solar-plus-storage solutions.

These initiatives not only bolster CATL's local service capabilities and market confidence, but also by enabling key partners, jointly drive the scaled adoption of comprehensive new energy solutions across the Middle East.

"As a leading energy company in Saudi Arabia, we see tremendous opportunities in energy transformation. For instance, we plan to deploy solar-plus-storage solutions at our gas stations and electrify forklifts to reduce reliance on oil. We look forward to collaborating with top players like CATL to drive this transition forward," said Ahmed Ibrahim，Assistant General Manager For Procurement of Al Drees, a leading provider of petroleum and logistics services in Saudi Arabia.

"The launch of CATL's Riyadh aftermarket flagship underscores our shared commitment to driving the global energy transition. This milestone not only reflects the growing demand for sustainable solutions in Saudi Arabia but also embodies our collective vision for a cleaner, electrified future. As the investor behind the experience centre, we are confident that this partnership will accelerate electrification and strengthen the region's role in advancing the energy transition." said Lin Chaofan, CEO of F4S. 

Part of a global network

The Saudi Arabia opening builds on CATL's global service footprint, which includes more than 1,200 professional service stations across 76 countries and 73 spare-parts warehouses worldwide. CATL ranks No. 1 globally in spare parts inventory stocked with 100% genuine parts, with a total warehouse area of more than 370,000 square meters. To date, NING SERVICE has supported more than six million electric vehicles, providing professional after-sales services for passenger vehicles, commercial vehicles, and energy storage customers.

A long-term commitment to the Middle East

Bruce Li, President of Quality System, Aftermarket Business, Battery Management System Department at CATL, said the Riyadh center reflects a strategic, long-term view of the region.

"Our decision to establish this center in Riyadh is not only a commercial choice, but a long-term commitment," Li said. "As the first NING SERVICE Experience Center in the Middle East, it is more than a service facility. It is a new energy aftermarket ecosystem hub that brings together advanced technology, professional training, and industry collaboration—effectively connecting diverse stakeholders and resources to foster deeper synergy and sustainable growth across the region. Starting from here, CATL will continue to expand its after-sales service network across the Middle East, align closely with Saudi Arabia's Vision 2030, and support the region's energy transition through a reliable, end-to-end service system."

As the Middle East accelerates its shift toward electrification and energy storage adoption, CATL's expanded NING SERVICE presence is poised to deliver the technical reliability and sustained partnerships essential for this transformation.

 

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

CATL Opens Middle East's Largest New Energy Aftermarket Facility in Riyadh

CATL Opens Middle East's Largest New Energy Aftermarket Facility in Riyadh

CATL Opens Middle East's Largest New Energy Aftermarket Facility in Riyadh